Misonix, Inc. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, August 22, 2017
August 03 2017 - 4:16PM
Misonix, Inc. (NASDAQ:MSON), a provider of minimally invasive
therapeutic ultrasonic medical devices that enhance clinical
outcomes, announced today that it will report financial results for
the fourth quarter and fiscal year 2017 on Tuesday, August 22,
2017. The Company has scheduled a conference call that same day,
Tuesday, August 22, 2017, at 4:30 pm ET to review the results.
Interested parties can access the conference call by dialing
(844) 861-5497 or (412) 317-6579 or can listen via a live Internet
webcast, which is available in the Investor Relations section of
the Company’s website at www.misonix.com.
A teleconference replay of the call will be available for three
days at (877) 344-7529 or (412) 317-0088, confirmation # 10111207.
A webcast replay will be available in the Investor Relations
section of the Company’s website at www.misonix.com for 30
days.
About MisonixMisonix, Inc.
designs, develops, manufactures and markets therapeutic ultrasonic
medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a
combined market estimated in excess of $1.5 billion annually;
Misonix's proprietary ultrasonic medical devices are used in spine
surgery, neurosurgery, orthopedic surgery, wound debridement,
cosmetic surgery, laparoscopic surgery, and other surgical and
medical applications. Additional information is available on the
Company's website at www.misonix.com.
Safe Harbor StatementWith the
exception of historical information contained in this press
release, content herein may contain "forward looking statements"
that are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based on management's current expectations and are subject to
uncertainty and changes in circumstances. Investors are cautioned
that forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from the
statements made. These factors include general economic conditions,
delays and risks associated with the performance of contracts,
risks associated with international sales and currency
fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying
levels of statistical relevancy, risks involved in introducing and
marketing new products, potential acquisitions, consumer and
industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing
of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated
510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, the impact of the pending
investigation by the Department of Justice and Securities Exchange
Commission, and other factors discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended June 30, 2016,
subsequent Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. The Company disclaims any obligation to update its
forward-looking relationships.
Company Contact:
Joe Dwyer
Misonix, Inc.
631-927-9113
jdwyer@misonix.com
www.misonix.com
Investor Contacts:
Robert Blum, Joe Dorame, Joe Diaz
Lytham Partners, LLC
602-889-9700
mson@lythampartners.com
www.lythampartners.com
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Sep 2023 to Sep 2024